Alexandre T Assaf1, Tomislav A Zrnc2, Björn Riecke2, Johannes Wikner2, Jozef Zustin3, Reinhard E Friedrich2, Max Heiland2, Ralf Smeets2, Alexander Gröbe2. 1. Department of Oral and Maxillofacial Surgery (Head: Professor Max Heiland MD, DMD, PhD), University Medical Center Hamburg Eppendorf, University of Hamburg, 20246 Hamburg, Germany. Electronic address: a.assaf@uke.uni-hamburg.de. 2. Department of Oral and Maxillofacial Surgery (Head: Professor Max Heiland MD, DMD, PhD), University Medical Center Hamburg Eppendorf, University of Hamburg, 20246 Hamburg, Germany. 3. Department for Pathology, University Medical Center Hamburg Eppendorf, University of Hamburg, Martinistr. 52, 20246 Hamburg, Germany.
Abstract
OBJECTIVES: The purpose of this study was to determine the potential of tissue fluorescence imaging by using Visually Enhanced Lesion Scope (VELscope) for the detection of osteonecrosis of the jaw induced by bisphosphonates (BRONJ). METHODS: We investigated 20 patients (11 females and 9 males; mean age 74 years, standard deviation ± 6.4 years), over a period of 18 month with the diagnosis of BRONJ in this prospective cohort study. All patients received doxycycline as a fluorescending marker for osseous structures. VELscope has been used intraoperatively using the loss of fluorescence to detect presence of osteonecrosis. Osseous biopsies were taken to confirm definite histopathological diagnosis of BRONJ in each case. RESULTS: Diagnosis of BRONJ was confirmed for every patient. In all patients except one, VELscope was sufficient to differentiate between healthy and necrotic bone by visual fluorescence retention (VFR) and visual fluorescence loss (VFL). 19 cases out of a total of 20 showed no signs of recurrence of BRONJ during follow-up (mean 12 months, range 4-18 months). CONCLUSION: VELscope examination is a suitable tool to visualize necrotic areas of the bone in patients with bisphosphonate related osteonecrosis of the jaw. Loss of fluorescence in necrotic bone areas is useful intraoperatively as a tool for fluorescence-guided bone resection with relevant clinical interpretation.
OBJECTIVES: The purpose of this study was to determine the potential of tissue fluorescence imaging by using Visually Enhanced Lesion Scope (VELscope) for the detection of osteonecrosis of the jaw induced by bisphosphonates (BRONJ). METHODS: We investigated 20 patients (11 females and 9 males; mean age 74 years, standard deviation ± 6.4 years), over a period of 18 month with the diagnosis of BRONJ in this prospective cohort study. All patients received doxycycline as a fluorescending marker for osseous structures. VELscope has been used intraoperatively using the loss of fluorescence to detect presence of osteonecrosis. Osseous biopsies were taken to confirm definite histopathological diagnosis of BRONJ in each case. RESULTS: Diagnosis of BRONJ was confirmed for every patient. In all patients except one, VELscope was sufficient to differentiate between healthy and necrotic bone by visual fluorescence retention (VFR) and visual fluorescence loss (VFL). 19 cases out of a total of 20 showed no signs of recurrence of BRONJ during follow-up (mean 12 months, range 4-18 months). CONCLUSION: VELscope examination is a suitable tool to visualize necrotic areas of the bone in patients with bisphosphonate related osteonecrosis of the jaw. Loss of fluorescence in necrotic bone areas is useful intraoperatively as a tool for fluorescence-guided bone resection with relevant clinical interpretation.
Authors: A M Pabst; M Krüger; K Sagheb; T Ziebart; C Jacobs; S Blatt; E Goetze; C Walter Journal: Clin Oral Investig Date: 2016-05-12 Impact factor: 3.573
Authors: Suad Aljohani; Riham Fliefel; Teresa Franziska Brunner; Aristeidis Chronopoulos; Nada Binmadi; Sven Otto Journal: J Int Med Res Date: 2022-06 Impact factor: 1.573
Authors: Oliver Ristow; Dirk Nehrbass; Stephan Zeiter; Daniel Arens; Julius Moratin; Christoph Pautke; Jürgen Hoffmann; Christian Freudlsperger; Sven Otto Journal: Clin Oral Investig Date: 2020-05-22 Impact factor: 3.573
Authors: Oliver Ristow; Lena Hürtgen; Julius Moratin; Maximilian Smielowski; Christian Freudlsperger; Michael Engel; Jürgen Hoffmann; Thomas Rückschloß Journal: J Korean Assoc Oral Maxillofac Surg Date: 2021-04-30